Transmeta Corporation Confirms First LongRun2 Licensee Has Achieved Volume Production
Transmeta zu myNews hinzufügen Was ist das?
Transmeta Corporation (NASDAQ: TMTA) today confirmed that its first
licensee began its production ramp of the first commercial product
licensed to use Transmeta’s LongRun2
technologies and has achieved volume production levels. As a result,
Transmeta expects to recognize approximately $215,000 in royalty revenue
in the first quarter of 2008 for products using Transmeta’s
LongRun2 technologies that were sold by its licensee during the fourth
quarter of 2007. This compares with sample production royalty revenues
of approximately $1,000 and $2,000 that the Company recognized from its
first licensee in the third and fourth quarters of 2007, respectively.
"We are very pleased that the first commercial
product licensed to use our LongRun2 technologies is now in volume
production,” said Les Crudele, president and
chief executive officer of Transmeta. "This is
an important milestone and highlights the long-term opportunity of our
IP licensing business.” About Transmeta Corporation
Transmeta Corporation develops and licenses innovative computing,
microprocessor and semiconductor technologies and related intellectual
property. Founded in 1995, we first became known for designing,
developing and selling our highly efficient x86-compatible
software-based microprocessors, which deliver a balance of low power
consumption, high performance, low cost and small size suited for
diverse computing platforms. We are presently focused on developing and
licensing our advanced power management technologies for controlling
leakage and increasing power efficiency in semiconductor and computing
devices, and in licensing our computing and microprocessor technologies
to other companies. To learn more about Transmeta, visit www.transmeta.com.
Safe Harbor Statement
This release contains forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such statements speak only as of the date of this release, and
we will not necessarily provide updates of our projections or other
forward-looking statements. Investors are cautioned that such
forward-looking statements are subject to many risks and uncertainties,
and may differ materially or adversely from our actual results or future
events. Important risk factors that could have material or adverse
effects on our results include uncertainty about the adoption and market
acceptance of our technology offerings by current and potential
customers and licensees, our inability to predict or ensure that third
parties will license our technologies or use our technologies to
generate royalties, difficulties in developing our technologies in a
timely and cost effective manner, and other risk factors. We urge
investors to review our filings with the Securities and Exchange
Commission, including our most recent reports on Forms 10-Q, 10-K and
8-K, which describe these and other important risk factors that could
have an adverse effect on our results. We undertake no obligation to
revise or update publicly any forward-looking statement for any reason.
Transmeta and LongRun2 are trademarks of Transmeta Corporation. All
other product or service names mentioned herein are the trademarks of
their respective owners.
